# American sunscreen is a lie

Source: https://www.youtube.com/watch?v=SvdmSE5IVRs
Recap page: https://rapidrecap.app/video/SvdmSE5IVRs
Generated: 2025-07-31T12:33:51.482+00:00

---
## Quick Overview

American sunscreens lag behind international formulations due to the FDA's stringent and outdated drug-based regulation of UV filters, leading to less effective and less comfortable products compared to those available in Europe and Asia. This regulatory environment, requiring extensive and costly new drug applications for each filter, has resulted in a limited selection of approved ingredients, with the last new filter approved in 1999, while other regions utilize over 30.


**Key Points:**
- American sunscreens are considered inferior due to the US FDA regulating them as drugs, a process that significantly slows the approval of new, more effective UV filters compared to cosmetic regulations in Europe and Asia.
- The US has only 16 approved UV filters, with the last new one approved in 1999, while other regions like the EU have over 30, leading to less comfortable and less comprehensive protection, particularly against UV-A rays.
- SPF ratings in the US only measure protection against UV-B rays (sunburn) and do not fully reflect UV-A protection, which is crucial for preventing aging and cancer.
- Dr. Michelle Wong, a cosmetic chemist, states, "The problem is that in Europe and Asia, they have much better ingredients," and notes that "wearability" is a major issue for American sunscreens.
- International sunscreens, especially Korean brands, gained popularity in the US for their improved formulations, but many were pulled from shelves or reformulated due to US regulations after a 2022 law expanded the FDA's authority.
- The FDA plans to reduce animal testing requirements and potentially accept safety data from other countries, which could accelerate the approval of new sunscreen ingredients in the US.
- Christophe quotes, "We are basically living in the sunscreen stone age here in America," reflecting the sentiment that the US is lagging significantly behind other countries in sunscreen technology and availability.

**Context:** The video investigates why American sunscreens are perceived as inferior to those available internationally, particularly from Asian and European markets. It highlights a significant gap in product quality and comfort, attributing it to the United States' regulatory framework for sunscreens. The host, Christophe, explores the science behind sunscreen and interviews experts to understand the root causes of this disparity, which impacts Americans' ability to protect themselves effectively against rising skin cancer rates.

## Detailed Analysis

The video explains that American sunscreens are considered inferior to those from countries like Japan, France, Australia, and South Korea due to differences in regulatory approaches to UV filters. In the US, sunscreens are regulated as over-the-counter drugs, a process that is slow, expensive, and requires companies to conduct extensive testing, including animal studies, for each new ingredient. This has led to a limited number of approved UV filters (16, with only about half in common use) and the last new approval occurring in 1999. In contrast, Europe and Asia regulate sunscreens as cosmetics, allowing for faster approval of new, more effective, and comfortable ingredients. For instance, the ingredient Bemotrizinol, widely used abroad and offering high UV-A protection, has been under FDA review for over 20 years. This regulatory bottleneck results in US sunscreens that can be greasy, smelly, or less effective, particularly in blocking UV-A rays, which contribute to aging and cancer. The effectiveness of sunscreen is explained using a UV camera: chemical filters absorb UV light and appear dark, while physical filters reflect it and appear white. Experts like cosmetic chemist Dr. Michelle Wong highlight that the US has fewer filters, especially for UV-A, and that the "wearability" of American sunscreens is a major issue for consumers. The demand for better sunscreens led to the popularity of international brands in the US, but a 2022 law expanded the FDA's authority, causing many international brands to reformulate with older US-approved filters or withdraw from the market. While there are efforts to update the FDA process, including a plan to reduce animal testing and utilize data from other countries, the fundamental regulatory hurdles remain. The video concludes that the US's overly cautious approach to public health has inadvertently led to inferior products, leaving Americans with fewer and less comfortable options for sun protection.

### Video Type

- Documentary
- News

### Key Topics

- US vs. international sunscreen regulations
- UV filters and their mechanisms
- FDA approval process for sunscreens
- Consumer experience with sunscreen wearability
- Impact of regulation on product availability

### Key People

- Christophe (host)
- Dr. Michelle Wong (cosmetic chemist)
- Carl D'Ruiz (DSM-Firmenich)

### Key Concepts

- Chemical vs. physical sunscreen filters
- UV-A vs. UV-B rays
- SPF rating limitations
- Over-the-counter drug regulation
- Cosmetic regulation

### Key Quotes

- "We are basically living in the sunscreen stone age here in America."
- "The problem is that in Europe and Asia, they have much better ingredients."
- "SPF just measures what proportion of the sun's radiation is making it through to your skin. But it's actually only a measure of how well a sunscreen protects against sunburns. So it only refers to defence against UV-B rays."

### Regulatory Differences

- US regulates sunscreens as drugs, leading to slow approval of new UV filters
- Europe and Asia regulate sunscreens as cosmetics, allowing faster adoption of new ingredients
- US has 16 approved UV filters, last new one approved in 1999
- EU has over 30 approved UV filters

### Consumer Impact

- American sunscreens are often described as greasy, smelly, and less comfortable than international options
- Lack of effective UV-A filters in many US sunscreens
- International sunscreens became popular in the US but faced regulatory crackdowns

### Path to Improvement

- FDA plans to reduce animal testing and use computer simulations/lab-grown tissue
- FDA may use safety data from countries with comparable standards
- Congressional efforts to speed up approval process have not yet succeeded